NCT04146324 - An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

December 12, 2019

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions

Melanoma

Interventions

DRUG

nivolumab

Administered as adjuvant therapy as per the market authorization in Australia

Trial Locations (9)

Local Institution, Garran

Local Institution, Box Hill

Local Institution, Malvern

Local Institution, Woolloongabba

Local Institution, Herston

Local Institution, Greenslopes

Local Institution, Birtinya

Local Institution, Cairns

Local Institution - 0006, Woodville South